Transcript EDCTP Activities

22 March 2012
Europe and ACP together against
tuberculosis
European Parliament, Rue Wiertz 60
BRUSSELS
Charles S Mgone
EDCTP Executive Director
The global burden of
tuberculosis
• A third of the global population i.e. over 2 billion
people are infected with the organism that causes TB
• 10% of the infected individuals eventually develop TB
disease in their lifetime with around 9.5 million news
cases and 2 million deaths occurring each year
• Drug resistance and HIV adds to the burden
• Lack of effective and adequate tools for diagnosis,
treatment and prevention of the disease exacerbates
the problem
Working in partnerships
through EDCTP
Participating
European
Member
States
Sub-Saharan
African
Countries
• Partnerships with highburdened countries
EDCTP
European
Commission
• Coordination of national
programmes
International
Development
Partners
PDPs
Pharma/SMEs
• Capacity development
and networking
• Synergy among R&D
international partners
The EDCTP partnership
EDCTP-EEIG member states
•
•
•
•
•
•
•
•
•
•
Austria
Belgium
Denmark
France
Germany
Greece
Ireland
Italy
Luxembourg
Netherlands
Norway
Portugal
Spain
• Sweden
• Switzerland
• United Kingdom
•
•
•
Sub-Saharan African countries
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Benin
• Malawi
Botswana
• Mali
Burkina Faso
• Mozambique
Cameroon
• Namibia
Congo
• Nigeria
Cote d’Ivoire
• Rwanda
Democratic Republic of Congo • Senegal
Ethiopia
• South Africa
Gabon
• Sudan
Ghana
• Tanzania
Guinea
• The Gambia
Guinea-Bissau
• Togo
Guinea-Conakry
• Uganda
Kenya
• Zambia
Liberia
• Zimbabwe
Madagascar
TB diagnostics and biomarkers
• Simple, accurate and efficient tools for diagnosing
TB, especially at the point of care are lacking
• Diagnosis in children and HIV-infected individuals is
problematic
• Vaccine studies are handicapped by the lack of
correlates of immune protection
There is therefore an urgent need to invest in
research on new diagnostics and biomarkers that
will help us to accurately diagnose TB and
understand better immunity against the disease
Vaccines development
BCG – the current vaccine in use since 1921 is far
from ideal
Newer vaccines are emerging along the pipeline with
EDCTP through North-South partnerships funding
several phase II clinical trials of some of them
There is a need to rationally plan phase III
trials in terms of the clinical trials designs and
funding
TB treatment
The current TB treatment regimens require long
periods from start to cure and are cumbersome
requiring patients to take many pills
This often results in poor adherence to treatment,
which in turn encourages drug resistance
TB treatment clinical trials
• Drug sensitive TB
• Shortening and simplification of the current treatment
regimens (The Pan-African Consortium for Evaluation of Antituberculosis Antibiotics – PanACEA): 11 African, 10 European
institutions + Global TB Alliance, Sequella, Bayer, BMGF
• HIV/TB co-infection
• Treatment optimisation
• Safety profiling
• Drug resistant TB
• Nearly 0.5 million cases world-wide (China, India, Russian
Federation contributing 50% of the cases)
Capacity development and
networking
• National Regulatory Authorities and Ethics Review
Committees support
• Personnel training (Long- and short-term)
• Research infrastructure support
• Clinical trial sites upgrade
• Laboratory improvements/accreditation
• Policy, governance and health systems strengthening
Thank you
http://www.edctp.org